PMID- 38274885
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240128
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 14
DP  - 2023
TI  - One-year retention of gait speed improvement in stroke survivors after treatment 
      with a wearable home-use gait device.
PG  - 1089083
LID - 10.3389/fneur.2023.1089083 [doi]
LID - 1089083
AB  - BACKGROUND: Gait impairments after stroke are associated with numerous physical 
      and psychological consequences. Treatment with the iStride((R)) gait device has 
      been shown to facilitate improvements to gait function, including gait speed, for 
      chronic stroke survivors with hemiparesis. This study examines the long-term gait 
      speed changes up to 12 months after treatment with the gait device. METHODS: 
      Eighteen individuals at least one-year post-stroke completed a target of 12, 
      30-minute treatment sessions with the gait device in their home environment. Gait 
      speed was measured at baseline and five follow-up sessions after the treatment 
      period: one  week, one  month, three months, six months, and 12 months. Gait 
      speed changes were analyzed using repeated-measures ANOVA from baseline to each 
      follow-up time frame. Additional analysis included comparison to the minimal 
      clinically important difference (MCID), evaluation of gait speed classification 
      changes, and review of subjective questionnaires. RESULTS: Participants retained 
      an average gait speed improvement >0.21 m/s compared to baseline at all 
      post-treatment time frames. Additionally, 94% of participants improved their gait 
      speed beyond the MCID during one or more post-treatment measurements, and 88% 
      subjectively reported a gait speed improvement. CONCLUSION: Treatment with the 
      gait device may result in meaningful, long-term gait speed improvement for 
      chronic stroke survivors with hemiparetic gait impairments. CLINICAL TRIAL 
      REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT03649217, identifier 
      NCT03649217.
CI  - Copyright (c) 2024 Darcy, Rashford, Tsai, Huizenga, Reed and Bamberg.
FAU - Darcy, Brianne
AU  - Darcy B
AD  - Moterum Technologies, Inc., Salt Lake City, UT, United States.
FAU - Rashford, Lauren
AU  - Rashford L
AD  - Moterum Technologies, Inc., Salt Lake City, UT, United States.
FAU - Tsai, Nancey T
AU  - Tsai NT
AD  - Moterum Technologies, Inc., Salt Lake City, UT, United States.
FAU - Huizenga, David
AU  - Huizenga D
AD  - Moterum Technologies, Inc., Salt Lake City, UT, United States.
FAU - Reed, Kyle B
AU  - Reed KB
AD  - Department of Mechanical Engineering, University of South Florida, Tampa, FL, 
      United States.
FAU - Bamberg, Stacy J M
AU  - Bamberg SJM
AD  - Moterum Technologies, Inc., Salt Lake City, UT, United States.
LA  - eng
SI  - ClinicalTrials.gov/NCT03649217
PT  - Journal Article
DEP - 20240111
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC10808505
OTO - NOTNLM
OT  - gait device
OT  - gait speed
OT  - iStride
OT  - retention
OT  - stroke rehabilitation
OT  - walking speed
COIS- KR has a patent (US 9,295,302) related to this work. A management plan has been 
      implemented and followed to reduce any effects of these conflicts of interest. 
      The gait device is related to a commercial product by Moterum Technologies, Inc. 
      BD, LR, DH, and SB receive a salary from Moterum Technologies. BD, LR, NT, DH, 
      KR, and SB have stock options in Moterum Technologies, Inc.
EDAT- 2024/01/26 06:44
MHDA- 2024/01/26 06:45
PMCR- 2024/01/11
CRDT- 2024/01/26 04:00
PHST- 2022/11/03 00:00 [received]
PHST- 2023/12/07 00:00 [accepted]
PHST- 2024/01/26 06:45 [medline]
PHST- 2024/01/26 06:44 [pubmed]
PHST- 2024/01/26 04:00 [entrez]
PHST- 2024/01/11 00:00 [pmc-release]
AID - 10.3389/fneur.2023.1089083 [doi]
PST - epublish
SO  - Front Neurol. 2024 Jan 11;14:1089083. doi: 10.3389/fneur.2023.1089083. 
      eCollection 2023.